    
The links after "Participants" show which Southwest Oncology Group institutions are eligible to participate in this study.
The orange "Where is This Study Open?" tab at the bottom of the page shows the institutions whose Institutional Review Boards (IRBs) have approved the protocol so that it can be opened at that institution. Clicking on the Institution Name will show the points of contact for information about this study at that institution.
|
|
CTSU/CALGB-40302
- Phase III Status Notes: This study is permanently closed to accrual effective July 14, 2010.
|
Endocrine Therapy with or without Inhibition of EGF and GER2 Growth Factor Receptors: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Fulvestrant with or without Lapatinib (GW572016) for Postmenopausal Women with Estrogen-Receptor Positive Advanced Breast Cancer
|
|
Treatment: Fulvestrant, Lapatinib
Disease Committee: Breast Cancer
|
|
Study Coordinator(s): Helen K. Chew, M.D. Participants: CTSU Eligibility Criteria: The Southwest Oncology Group has endorsed this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Please contact the CTSU directly by either phone (1-888-823-5923) or on the CTSU web site (http://www.ctsu.org/) for information and registration procedures.
|
Activation Date: 9/1/2006
|
| IRB approval information is not available for CTSU protocols |
